Esketamine Quiz

Q1. Esketamine is administered via which route?

A) Intranasal spray

B) Oral tablet

C) Intramuscular injection

D) Subcutaneous injection

Q2. What is Esketamine FDA-approved to treat?

A) Treatment-resistant depression

B) Bipolar disorder

C) Schizophrenia

D) Generalized anxiety disorder

Q3. Which receptor does Esketamine primarily antagonize to exert its therapeutic effects?

A) NMDA receptor

B) GABA receptor

C) Dopamine receptor

D) Serotonin receptor

Q4. What is the recommended frequency of Esketamine administration during the induction phase for treatment-resistant depression?

A) Twice weekly

B) Once weekly

C) Every other week

D) Once monthly

Q5. Which serious side effect requires monitoring after each administration of Esketamine?

A) Dissociation

B) Hypertension

C) Sedation

D) All of the above

Q6. Esketamine is contraindicated in patients with which of the following conditions?

A) Aneurysmal vascular disease

B) Mild hepatic impairment

C) Controlled hypertension

D) Hyperlipidemia

Q 7.Which enzyme is primarily involved in the metabolism of Esketamine?

A) CYP2B6 & CYP3A4

B) Non CYP Pathway

C) CYP2D6

D) CYP1A2

Q8. What is the black box warning associated with Esketamine?

A) Sedation, dissociation, and potential for abuse and misuse

B) Hepatotoxicity

C) QT prolongation

D) Serotonin syndrome

Q9.Which population requires close monitoring during Esketamine therapy due to an increased risk of adverse effects?

A) Elderly patients

B) Pediatric patients

C) Pregnant women

D) All of the above

Q10. Which of the following is a critical step in the administration of Esketamine to ensure safety?

A) Observation for at least two hours post-administration

B) Pre-medication with benzodiazepines

C) Combining with SSRIs for all patients

D) Administration in a home setting

Esketamine (Spravato) Medication